SCHEMBL2373975

SCHEMBL2373975

C=C(c1ccc(O)cc1)c1cnc(OCCOCCOCCF)c(I)c1

nearest known ligand 0.64

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
APP P05067 18/20 0.64
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
GFER P55789 1/20 0.36
HSD17B10 Q99714 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
CYP1B1 Q16678 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2374823 0.86 APP (0.65) APPMAPT
SCHEMBL2373471 0.86 APP (0.65) APPMAPT
SCHEMBL2386945 0.86 APP (0.64) APPMAPTHTTGFERHSD17B10
SCHEMBL2373969 0.78 APP (1.00) APPMAPTHSD17B10
SCHEMBL2373979 0.78 APP (1.00) APPMAPTHSD17B10
SCHEMBL2374404 0.78 APP (0.42) APP
SCHEMBL2374229 0.73 APP (0.65) APPMAPT
SCHEMBL2374189 0.73 APP (0.65) APPMAPT
SCHEMBL2374230 0.72 APP (0.63) APP
SCHEMBL2374217 0.72 APP (0.63) APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2363392-B1 STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES UNIV PENNSYLVANIA (US) 2017-05-03 EP disclosed
US-8840866-B2 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2014-09-23 US disclosed
US-8506929-B2 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2013-08-13 US disclosed
US-20130129624-A1 STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2013-05-23 US disclosed
EP-1999109-B1 STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES UNIV PENNSYLVANIA (US) 2011-12-28 EP disclosed
EP-2363391-A1 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques The Trustees of The University of Pennsylvania (US) 2011-09-07 EP disclosed
EP-2363392-A1 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques The Trustees of The University of Pennsylvania (US) 2011-09-07 EP disclosed
US-7687052-B2 radiolabeling; neurodegenerative diseases THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2010-03-30 US disclosed
US-20090123369-A1 Styrylpyridine Derivatives and Their Use for Binding and Imaging Amyloid Plaques THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2009-05-14 US disclosed
US-20080038195-A1 radiolabeling; neurodegenerative diseases THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2008-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130129624-A1 STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES APP, APBA1, PSEN1 APP 1/4885MAPT 7/4885HTT 29/4885
US-20080038195-A1 radiolabeling; neurodegenerative diseases APP, PSEN1, HTT APP 1/4885MAPT 6/4885HTT 3/4885
US-20090123369-A1 Styrylpyridine Derivatives and Their Use for Binding and Imaging Amyloid Plaques APP, APBA1, PSEN1 APP 1/4885MAPT 7/4885HTT 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.